Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up

on

Viva Biotech reported 2025 revenue of RMB1,729.4 million with gross profit of RMB655.6 million and gross profit margin of 37.9%, up 3.3 percentage points year-over-year1

Net profit reached RMB269.3 million, representing a 21.3% year-on-year increase, while adjusted non-IFRS net profit increased 6.6% to RMB335.3 million1

CRO business revenue grew to RMB848.6 million in 2025, up 4.7% from RMB810.9 million the previous year, with adjusted gross profit increasing 7.3%1

The company increased its CRO client base to 1,866 clients, including top-ten global pharmaceutical companies accounting for 25.7% of total revenue1

Viva Biotech delivered over 98,885 protein structures to clients, including 16,169 newly delivered structures in 2025, covering more than 2,345 independent drug targets1

Revenue from AI-enabled drug discovery (AIDD) projects accounted for 12.0% of total CRO revenue, with 196 total projects supported by AIDD and 73 clients purchasing CADD/AIDD services1

Novel molecular modalities revenue represented 15.8% of CRO revenue, showing an 11.0% year-over-year increase and emerging as a new growth driver1

The company collaborated with NVIDIA to advance AI-driven drug discovery through the 'Lab-in-the-Loop' workflow, combining computational design with experimental validation3

Viva Biotech's incubation portfolio companies achieved full or partial exits for 19 projects, with a total of nearly 231 pipelines under research including 187 at the pre-clinical stage and 44 at the clinical stage1

Sources:

1. https://www.prnewswire.com/news-releases/viva-biotech-announces-2025-annual-results-ai-driven-drug-discovery-reinforces-industry-leadership-cdmo-commercial-products-enter-rapid-scale-up-302728790.html

3. https://www.prnewswire.co.uk/news-releases/viva-biotech-accelerates-ai-driven-drug-discovery-and-advance-the-lab-in-the-loop-with-nvidia-302714744.html